Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05996445 · ClinicalTrials.gov registry record · Phase 1
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
A Phase 1 study, sponsored by Xencor.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT05996445 is a Phase 1 study that was terminated before completion, run by Xencor. The registered enrollment target is 7 participants.
The verdict
NCT05996445, a Phase 1 study, was terminated before completion, sponsored by Xencor.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous administration of XmAb662 monotherapy or in combination with pembrolizumab in subjects with advanced solid tumors and to identify the recommended dose regimen that is safe and biologically effective for XmAb662.
Interventions
- BIOLOGICAL Keytruda® (pembrolizumab)
- BIOLOGICAL XmAb662
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-07-28 |
| Est. Completion | 2024-05-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05996445
The ClinicalTrials.gov registry entry for NCT05996445 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Keytruda® (pembrolizumab) is the first listed.
NCT05996445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05996445 about?
NCT05996445 is a clinical study titled "A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous administration of XmAb662 monotherapy or in combination with pembrolizumab in subjects with advanced solid tumors and to identify the recommended dose regimen that is safe and biologically effectiv...
What is the current status of trial NCT05996445?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2023-07-28. Estimated completion is 2024-05-21.
What interventions are being tested in trial NCT05996445?
The interventions under investigation include: Keytruda® (pembrolizumab) (BIOLOGICAL), XmAb662 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05996445?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.